Affinage

JMJD6

Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 · UniProt Q6NYC1

Length
403 aa
Mass
46.5 kDa
Annotated
2026-04-28
100 papers in source corpus 45 papers cited in narrative 44 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JMJD6 is a nuclear Fe(II)- and 2-oxoglutarate-dependent dioxygenase that functions as both a lysyl-5-hydroxylase and an arginine demethylase, coupling post-translational modification of diverse protein substrates to transcriptional regulation, alternative pre-mRNA splicing, and stress responses. Its primary enzymatic activity is C-5 lysyl hydroxylation — producing the 5S-stereoisomer — of unstructured lysine-rich regions on dozens of substrates including U2AF65, BRD4, histones, p53, and fibronectin, thereby modulating splicing factor recruitment, chromatin modification crosstalk, and protein homeostasis (PMID:19574390, PMID:35930668, PMID:22238144). JMJD6 also demethylates histone H4R3me2s/a and non-histone substrates (STAT1, G3BP1, p65, HSP70), and cooperates with BRD4 at anti-pause enhancers to release P-TEFb from the 7SK snRNP — via both H4R3me2s erasure and proteolytic cleavage of MePCE — enabling RNA Pol II pause release and productive transcriptional elongation (PMID:24360279, PMID:32048991, PMID:29628309). Loss of Jmjd6 in mice causes defective hematopoietic stem cell self-renewal through elevated mitochondrial OXPHOS and ROS, impairs Aire pre-mRNA splicing leading to multi-organ autoimmunity, and compromises rDNA damage responses (PMID:33560400, PMID:26531897, PMID:32598339).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2007 High

    Establishing JMJD6 as a JmjC-family dioxygenase with histone arginine demethylase activity resolved its enzymatic classification and linked it to epigenetic regulation of H3R2 and H4R3 marks.

    Evidence In vitro enzymatic assay and cell-based histone demethylation assays

    PMID:17947579

    Open questions at the time
    • Whether arginine demethylation is a primary or secondary activity was not resolved
    • Substrate specificity beyond histones was unknown
    • No structural basis for catalysis
  2. 2009 High

    Discovery that JMJD6 catalyzes Fe(II)/2OG-dependent lysyl-5-hydroxylation of U2AF65 revealed an unexpected second enzymatic activity and directly connected JMJD6 to alternative splicing regulation.

    Evidence In vitro enzymatic reconstitution, mass spectrometry, and splicing reporter assays with siRNA knockdown

    PMID:19574390

    Open questions at the time
    • Whether lysyl hydroxylation or arginine demethylation is the dominant activity remained debated
    • The full spectrum of lysyl hydroxylation substrates was unknown
    • How hydroxylation mechanistically alters U2AF65 splicing activity was not defined
  3. 2010 High

    Crystal structures revealed the DSBH fold, iron coordination, and single-stranded RNA-binding surface of JMJD6, providing the structural framework to interpret its dual catalytic activities and RNA-dependent functions.

    Evidence X-ray crystallography, active-site mutagenesis, and RNA-binding assays

    PMID:20679243 PMID:20684070 PMID:20685276

    Open questions at the time
    • How ssRNA binding modulates catalytic activity was unclear
    • No co-crystal with a peptide substrate was available
    • Oligomerization mechanism was structurally unresolved
  4. 2011 High

    Stereochemical assignment of JMJD6-catalyzed hydroxylation as 5S-hydroxylysine distinguished it from collagen lysyl hydroxylases and established a new dioxygenase subfamily, while functional studies linked JMJD6-U2AF65 interaction to VEGFR1/Flt1 splicing and angiogenesis.

    Evidence Amino acid analysis with stereochemical characterization; Co-IP, splicing analysis, and angiogenesis rescue assays in endothelial cells

    PMID:21300889 PMID:22238144

    Open questions at the time
    • Whether JMJD6 hydroxylase activity is required for angiogenic splicing was not tested with catalytic mutants
    • Downstream signaling consequences of 5S- vs 5R-hydroxylysine were unexplored
  5. 2013 High

    The discovery that JMJD6 hydroxylates histone lysines (competing with acetylation/methylation) and co-occupies anti-pause enhancers with BRD4 to release P-TEFb from the 7SK snRNP complex established JMJD6 as a dual regulator of histone modification crosstalk and transcriptional elongation.

    Evidence In vitro hydroxylation with KO embryo histone analysis; ChIP-seq, Co-IP, RNA demethylation assay, and Pol II pausing readout

    PMID:23303181 PMID:24360279

    Open questions at the time
    • Which histone lysyl hydroxylation sites are most functionally consequential in vivo was undefined
    • The relative contributions of H4R3me2s demethylation vs 7SK RNA decapping to pause release were not separated
    • Iron availability as a regulatory variable for enhancer function was untested
  6. 2014 High

    Identification of p53-K382 hydroxylation that antagonizes acetylation and promotes MDMX binding, together with mapping of multiple SR/RS-domain splicing factor interactions, expanded JMJD6's substrate repertoire to a key tumor suppressor and a network of splicing regulators.

    Evidence Co-IP, in vitro hydroxylation/MS, acetylation competition assay, transcriptional reporter; pulldown with RS-domain proteins and splicing reporter

    PMID:24667498 PMID:24914048

    Open questions at the time
    • Whether p53 hydroxylation occurs at physiological JMJD6 levels was uncertain
    • The selectivity rules governing which RS domains are recognized were unknown
  7. 2015 High

    In vivo conditional knockout studies demonstrated that Jmjd6 is required for Aire pre-mRNA splicing in thymic epithelial cells and prevents multi-organ autoimmunity, providing the first direct genetic evidence linking JMJD6 splicing function to organismal physiology.

    Evidence Conditional KO mouse, RT-PCR splicing analysis, western blot, autoimmunity phenotype

    PMID:26531897

    Open questions at the time
    • Whether JMJD6 hydroxylase activity (vs scaffolding) is required for Aire splicing was not dissected
    • Broader splicing targets affected in thymic epithelium were not profiled genome-wide
  8. 2017 High

    Genome-wide splicing analyses in jmjd6 KO mice confirmed JMJD6 as a broad co-regulator of alternative splicing with U2AF65, while structural determination of the BRD4-ET/JMJD6 interface and identification of non-histone arginine demethylation substrates (G3BP1, HURP) broadened its functional scope to stress granules and cell migration.

    Evidence RASL-seq in KO mice with catalytic mutant rescue; NMR structure of BRD4-ET/JMJD6 complex; Co-IP with demethylation and SG/migration assays

    PMID:27899633 PMID:28972166 PMID:29176719 PMID:36250981

    Open questions at the time
    • How RNA binding allosterically promotes BRD4 interaction in cells was not validated
    • Whether G3BP1 demethylation is the primary mechanism of SG regulation or a secondary effect was unclear
    • The catalytic basis for arginine demethylase vs lysyl hydroxylase selectivity remained structurally unresolved
  9. 2018 Medium

    JMJD6 was positioned at ERα-bound enhancers where it enables Pol II recruitment, eRNA production, and MED12 methylation by CARM1, while parallel studies reported STAT1 and p65 arginine demethylation linking JMJD6 to interferon and NF-κB signaling, and a claimed intrinsic tyrosine kinase activity toward H2A.X.

    Evidence ChIP-seq, Co-IP, eRNA/Pol II pausing assays; KD/OE with methylation readouts; in vitro kinase assay with mutagenesis

    PMID:29628309 PMID:29693039 PMID:30185813 PMID:37186122

    Open questions at the time
    • The tyrosine kinase activity claim has not been independently replicated and conflicts with the known dioxygenase fold
    • Whether JMJD6 directly demethylates STAT1 or acts indirectly was not resolved with purified components
    • The relative contribution of catalytic vs scaffolding roles at ERα enhancers was not separated
  10. 2019 High

    Rigorous biochemical and structural re-examination confirmed JMJD6 as a lysyl hydroxylase and failed to reproduce arginine demethylase activity with purified enzyme, sharpening the debate about its primary catalytic function; separately, JMJD6-BRD4-N-Myc complexes were implicated in neuroblastoma transcription.

    Evidence MS- and NMR-based kinetic assays with multiple substrate sequences, X-ray crystallography; Co-IP and ChIP in neuroblastoma with in vivo KD

    PMID:31147442 PMID:31346162

    Open questions at the time
    • Cell-based arginine demethylation reported by multiple labs was not explained by the negative in vitro result — a cofactor or context-dependent mechanism may exist
    • Whether JMJD6 hydroxylates N-Myc directly was not tested
  11. 2020 High

    Discovery that JMJD6 cleaves MePCE to disrupt the 7SK snRNP provided a unifying proteolytic mechanism for P-TEFb liberation complementing H4R3me2s demethylation; concurrent studies revealed JMJD6 roles at DNA double-strand breaks (via SIRT1 recruitment) and rDNA damage sites (via Treacle interaction), and in suppressing antiviral innate immunity through RNF5-mediated IRF3 degradation.

    Evidence Crystal structure with cleavage reconstitution and KO validation; microirradiation and Co-IP at DSBs/nucleolar damage; proteomic screen with ubiquitination and viral replication assays

    PMID:31358914 PMID:32048991 PMID:32598339 PMID:33684176

    Open questions at the time
    • Whether MePCE cleavage is a general proteolytic activity or specific to 7SK snRNP context is unknown
    • How JMJD6 coordinates catalytic and non-catalytic (scaffolding) functions at DNA damage sites is unclear
    • The IRF3 degradation pathway was studied in one lab and independent confirmation is needed
  12. 2021 High

    Conditional hematopoietic KO established that Jmjd6 is essential for HSC self-renewal by restraining mitochondrial OXPHOS and ROS, while substrate studies identified fibronectin lysyl hydroxylation as a regulator of extracellular matrix assembly and demonstrated JMJD6-dependent U2AF65 recruitment to AR pre-mRNA governing AR-V7 splicing in prostate cancer.

    Evidence Serial transplantation with antioxidant rescue; MALDI-TOF substrate ID with fibronectin assembly assays; siRNA screen with RNA immunoprecipitation and catalytic mutagenesis

    PMID:33560400 PMID:33822745 PMID:34055782

    Open questions at the time
    • The direct JMJD6 substrates mediating HSC metabolic control are unidentified
    • Whether fibronectin hydroxylation is relevant in non-placental tissues is untested
    • Therapeutic targeting of the JMJD6-AR-V7 axis lacks pharmacological tool compounds
  13. 2022 High

    Large-scale proteomics identified 150 lysyl hydroxylation sites on 48 substrates — predominantly in disordered, lysine-rich regions of membraneless organelle components — suggesting JMJD6 may broadly regulate liquid-liquid phase separation; studies also linked JMJD6 with RBM39 at gene promoters driving lipid droplet formation in ccRCC.

    Evidence MS with lysine derivatization in JMJD6 KO cells; Co-IP and ChIP-seq/RNA-seq with in vivo tumor models

    PMID:35764091 PMID:35930668

    Open questions at the time
    • Functional validation of phase separation regulation by JMJD6 hydroxylation is lacking
    • Whether specific hydroxylation sites are more biologically consequential than others is unknown
    • The RBM39-JMJD6 interaction's dependence on catalytic activity was not tested
  14. 2024 Medium

    JMJD6 was connected to glutamine metabolism via alternative splicing of glutaminase isoforms in MYC-driven neuroblastoma and to the heat shock response through HSP70-R469 demethylation that sustains HSF1 activation, revealing new metabolic and proteostatic circuits.

    Evidence Co-IP with RNA-seq splicing and metabolic assays; genome-wide RNAi screen with methylation assay and ChIP

    PMID:38488852 PMID:38985769

    Open questions at the time
    • Whether glutaminase isoform switching is a direct consequence of JMJD6 hydroxylase activity or mediated through RBM39 is unresolved
    • The HSP70 demethylation finding is from a single lab and awaits independent confirmation
  15. 2025 Medium

    JMJD6 was shown to nucleate de novo enhancers at glutathione biosynthesis genes with Mediator and ATF4, linking SPOP-mutant prostate cancer JMJD6 accumulation to ferroptosis resistance — extending JMJD6's enhancer-assembly role beyond ERα targets.

    Evidence Co-IP (JMJD6-Med1/14-ATF4), ChIP-seq enhancer-promoter loops, ferroptosis assays, in vivo preclinical models

    PMID:39903850

    Open questions at the time
    • Whether JMJD6 catalytic activity is required for de novo enhancer formation is untested
    • The SPOP-JMJD6 degradation axis awaits structural characterization
    • Generalizability beyond SPOP-mutant prostate cancer is unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the mechanistic basis for context-dependent arginine demethylase vs lysyl hydroxylase selectivity, whether JMJD6-catalyzed hydroxylation of phase-separating substrates functionally alters condensate properties, and how JMJD6's catalytic and non-catalytic (scaffolding/proteolytic) activities are coordinately regulated in different nuclear compartments.
  • No reconstituted system resolves dual-activity selectivity rules
  • Phase separation regulation by JMJD6 hydroxylation is inferred from substrate identity but not experimentally demonstrated
  • No comprehensive separation-of-function allele series exists to assign catalytic vs scaffolding contributions across biological contexts

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 11 GO:0016491 oxidoreductase activity 8 GO:0098772 molecular function regulator activity 4 GO:0003723 RNA binding 2
Localization
GO:0005634 nucleus 4 GO:0005654 nucleoplasm 4 GO:0005730 nucleolus 2
Pathway
R-HSA-8953854 Metabolism of RNA 8 R-HSA-392499 Metabolism of proteins 6 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-4839726 Chromatin organization 3 R-HSA-168256 Immune System 2 R-HSA-73894 DNA Repair 2
Partners
BRD4MED12MEPCERBM39RNF5SIRT1TCEAL1U2AF65
Complex memberships
7SK snRNP (regulatory target)BRD4-JMJD6 complexU2AF65-containing spliceosome

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 JMJD6 is a JmjC-containing, iron- and 2-oxoglutarate-dependent dioxygenase that demethylates histone H3 at arginine 2 (H3R2) and histone H4 at arginine 3 (H4R3) in biochemical and cell-based assays. In vitro enzymatic assay, cell-based demethylation assays Science High 17947579
2009 JMJD6 catalyzes Fe(II)- and 2-oxoglutarate-dependent C-5 lysyl hydroxylation of the splicing factor U2AF65, and this activity modulates alternative RNA splicing of select endogenous and reporter genes. In vitro enzymatic assay, mass spectrometry, splicing reporter assays, siRNA knockdown Science High 19574390
2010 Crystal structure of JMJD6 reveals a double-stranded β-helical (DSBH) fold with active-site iron coordination; mutational studies show the structural basis for C-5 lysyl hydroxylation rather than Nε-demethylation. X-ray crystallography, active-site mutagenesis Journal of Molecular Biology High 20684070 20685276
2010 JMJD6 binds single-stranded RNA (but not ssDNA, dsRNA, or dsDNA) via positively charged surfaces revealed by structural analysis; a stack of aromatic residues near the active center undergoes conformational change upon alpha-ketoglutarate binding. X-ray crystallography, RNA-binding assays, truncation analysis Proceedings of the National Academy of Sciences High 20679243
2010 JMJD6 localizes throughout the nucleoplasm outside heterochromatic regions and is excluded from the nucleus during mitosis, re-entering at telophase; it forms homo-multimers in both nucleus and cytoplasm and associates preferentially with RNA/RNA complexes rather than chromatin; no histone lysine demethylase activity was detected. Immunolocalization, western blot (homo-multimer analysis), RNase/DNase treatment, KO cell comparison of histone methylation marks PLoS One High 21060799
2011 JMJD6 catalyzes 2-oxoglutarate-dependent C-5 hydroxylation of lysine residues to give 5S-hydroxylysine products, stereochemically distinct from collagen lysyl hydroxylases (which give 5R products), establishing a new subfamily of lysyl hydroxylases. Amino acid analysis, mass spectrometry, stereochemical assignment ChemBioChem High 22238144
2011 JMJD6 interacts with U2AF65 and regulates splicing of VEGF-receptor 1 (Flt1), shifting the ratio toward soluble Flt1 (sFlt1); silencing JMJD6 impairs angiogenic sprouting, which can be rescued by neutralizing sFlt1 or saturating VEGF/PlGF. siRNA knockdown, Co-IP, splicing analysis, angiogenesis rescue assays Proceedings of the National Academy of Sciences High 21300889
2012 JMJD6 homo-oligomerization requires its own enzymatic (hydroxylase) activity and both N- and C-termini; JMJD6 auto-hydroxylates its N-terminus in vitro, suggesting intermolecular covalent bond formation drives oligomerization; no arginine demethylase activity toward histone peptides was detected in vitro. MALDI-TOF mass spectrometry enzymatic assay, mutational analysis, in vitro hydroxylation assay Journal of Cellular Biochemistry Medium 22189873
2013 JMJD6 hydroxylates lysine residues of histone H3 and H4 tails in vitro and hydroxylates lysyl residues of histones H2A/H2B and H3/H4 in vivo; 5-hydroxylysine on histones inhibits N-acetylation and N-methylation by acetyltransferase and methyltransferase, respectively. In vitro binding/hydroxylation assays, amino acid composition analysis of KO embryos, HEK293 overexpression, competitive modification assays Journal of Biological Chemistry High 23303181
2013 JMJD6 and BRD4 co-occupy distal anti-pause enhancers (A-PEs); BRD4-dependent JMJD6 recruitment mediates erasure of H4R3me2s, which is read by 7SK snRNA; JMJD6 also decaps/demethylates 7SK snRNA, releasing the 7SK/HEXIM inhibitory complex from P-TEFb, enabling RNA Pol II promoter-proximal pause release. ChIP-seq, Co-IP, RNA demethylation assay, long-range chromatin interaction analysis, knockdown with Pol II pausing readout Cell High 24360279
2013 The polyserine (polyS) domain of JMJD6 mediates subnuclear localization; an alternatively spliced isoform lacking the polyS domain localizes to the nucleolar fibrillar centre and interacts with nucleolar proteins; homo-oligomerization is confirmed by Co-IP and F2H assays in cells. Immunofluorescence localization, Co-IP, F2H (fluorescent 2-hybrid) assay, electron microscopy of oligomers in vitro Biochemical Journal Medium 23688307
2014 JMJD6 physically associates with p53 and hydroxylates p53 at lysine 382 (an α-ketoglutarate- and Fe(II)-dependent reaction); this hydroxylation antagonizes p53 acetylation, promotes association of p53 with MDMX, and represses p53 transcriptional activity. Co-IP, in vitro hydroxylation assay, mass spectrometry, acetylation competition assay, transcriptional reporter assay, KD/KO proliferation/apoptosis readout PLoS Biology High 24667498
2014 JMJD6 interacts with methylated ERα (metERα) and demethylates it upon estrogenic stimulation, acting as an arginine demethylase of ERα to regulate rapid extranuclear estrogenic responses. Co-IP, JMJD6 silencing combined with demethylation assay PLoS One Medium 24498420
2014 JMJD6 interacts with multiple arginine-serine-rich (RS) domains of SR and SR-related splicing proteins (U2AF65, Luc7L3, SRSF11, Acinus S'), but not with the bona fide RS domain of SRSF1; it modifies a constitutive splice reporter, binds RNA derived from the reporter, and co-localizes with nascent RNA, suggesting RNA-dependent splice modulatory function. Co-IP/pulldown with RS-domain proteins, splicing reporter assay, RNA binding, immunofluorescence co-localization with nascent RNA Nucleic Acids Research High 24914048
2015 Jmjd6 is required for effective splicing out of intron 2 of the Aire gene; Jmjd6-deficient medullary thymic epithelial cells show normal Aire transcript abundance but markedly reduced mature Aire protein, leading to impaired self-antigen expression and spontaneous multi-organ autoimmunity. Conditional KO mouse model, RT-PCR splicing analysis, western blot, autoimmunity phenotype Nature Communications High 26531897
2015 JMJD6 binds to the p19ARF promoter and demethylates H4R3me2a, repressing p19ARF expression, thereby reducing p53 levels and suppressing Myc-induced apoptosis to cooperate with c-Myc in mammary tumorigenesis. ChIP, H4R3me2a demethylation assay, KO/overexpression in MMTV-Myc cells, tumor burden and metastasis analysis in mice Clinical Epigenetics Medium 27081402
2017 JMJD6 demethylates G3BP1 at three arginine residues (monomethylation and asymmetric dimethylation), is a component of stress granules, and promotes stress granule (SG) formation; knockdown of JMJD6 represses SG formation and G3BP1 demethylation, which is rescued by catalytically active but not mutant JMJD6. Co-IP, methylation assays, SG formation assays, catalytic mutant rescue Journal of Biological Chemistry Medium 28972166
2017 JMJD6 co-regulates alternative splicing of a large number of events together with U2AF65 in an RNA-dependent manner; JMJD6 enzymatic (lysine hydroxylase) activity is required for a subset of co-regulated splicing events; validated in jmjd6 knockout mice. RASL-seq, jmjd6 KO mouse, catalytic mutant complementation, splicing reporter assays Nucleic Acids Research High 27899633
2017 JMJD6 demethylates HURP at R122, promoting Golgi apparatus repositioning (GR) and directional cell migration; the HURP methylation-mimicking mutant blocks JMJD6-induced GR, and the effect is relayed through NF-κB-induced centrosome repositioning and Cdc42 upregulation. Demethylation assay, mutant rescue, GR imaging, NF-κB and Cdc42 functional assays Journal of Cellular Physiology Medium 36250981
2017 The extraterminal (ET) domain of BRD4 recognizes a JMJD6 peptide (Lys84-Asn96) that adopts an α-helix when bound; this interaction is established through JMJD6 contacts with the conserved hydrophobic core of the ET domain and is reinforced by electrostatic interactions; single-stranded RNA binding induces a conformational change in JMJD6 that likely promotes the JMJD6-BRD4 ET interaction. NMR structure determination, binding assays, mutational analysis Scientific Reports High 29176719
2018 JMJD6 is recruited to ERα-bound active enhancers and is required for RNA Pol II recruitment, enhancer RNA production, and transcriptional pause release of estrogen target genes; JMJD6 interacts with MED12 in the mediator complex and is necessary for CARM1 to methylate MED12 at multiple arginine sites, regulating MED12 chromatin binding. ChIP-seq, Co-IP, RNA Pol II pausing assay, enhancer RNA measurement, JMJD6 KD, CARM1 methylation assay Molecular Cell High 29628309
2018 JMJD6 has intrinsic tyrosine kinase activity and phosphorylates histone H2A.X at tyrosine 39 (H2A.XY39ph), using ATP and GTP as phosphate donors; elevated JMJD6 promotes autophagy in triple-negative breast cancer cells via this H2A.XY39ph axis. In vitro kinase assay, mutagenesis, autophagy pathway readout, KD/OE experiments Oncogene Medium 30185813
2018 JMJD6 demethylates STAT1 at arginine residues; JMJD6 overexpression suppresses STAT1 methylation and IFNα-induced interferon-stimulated gene (ISG) activation while increasing HCV RNA, whereas JMJD6 silencing enhances STAT1 methylation and ISG stimulation. JMJD6 KD/OE, STAT1 methylation western blot, ISG activation assay, HCV RNA quantification Cellular and Molecular Gastroenterology and Hepatology Medium 29693039
2018 JMJD6 demethylates the NF-κB p65 subunit at R149 in the cytoplasm, inhibiting nuclear translocation of p65 and thereby inactivating NF-κB signaling to protect against pathological cardiac hypertrophy; JMJD6 also demethylates histone H3R8. Co-IP, demethylation assay, cardiac-specific overexpression/depletion, nuclear fractionation, in vivo rat model Acta Pharmacologica Sinica Medium 37186122
2019 Biochemical and structural analyses (MS, NMR, crystallography) confirm JMJD6 as a lysyl hydroxylase; arginine N-demethylation activity could not be reproduced with purified JMJD6 using multiple substrate sequences; crystal structure of JMJD6Δ344-403 with iron and 2OG further supports lysyl hydroxylase assignment. MS- and NMR-based kinetic assays, X-ray crystallography, biophysical analyses Journal of Biological Chemistry High 31147442
2019 JMJD6 forms protein complexes with N-Myc and BRD4 in neuroblastoma cells and is important for transcription of E2F2, N-Myc, and c-Myc; JMJD6 knockdown reduces neuroblastoma cell proliferation and tumor progression in mice. Co-IP (complex formation), ChIP (super-enhancer association), KD with proliferation/survival and in vivo tumor readout Nature Communications Medium 31346162
2019 Promotion of adipogenesis by JMJD6 requires the AT hook-like domain (mediating interaction with DNA/RNA) but is independent of catalytic enzymatic activity; the AT hook-like domain is required for JMJD6 interaction with chromatin at adipogenic regulator genes. Domain mutational analysis, adipogenic differentiation assay, chromatin interaction assay, oligomerization analysis PLoS One Medium 31430278
2020 JMJD6 cleaves MePCE (methylphosphate capping enzyme), a core component of the 7SK snRNP complex, via a novel proteolytic activity; this disrupts the 7SK snRNP complex and, together with BRD4, enables P-TEFb recruitment to RNA Pol II CTD for productive elongation; crystal structure of JMJD6 bound to methyl-arginine supports the mechanism. Crystal structure, in vitro and in vivo cleavage assays, binding assays, Jmjd6 KO/OE with Pol II CTD phosphorylation readout eLife High 32048991
2020 JMJD6 is recruited to DNA double-strand breaks, controls spreading of histone ubiquitination and accumulation of repair proteins around DSBs, and modulates NHEJ and HR efficiency; independently of catalytic activity, JMJD6 interacts with SIRT1 and recruits it to chromatin to downregulate H4K16ac at DSBs. Microirradiation/live imaging, Co-IP, ChIP, NHEJ/HR reporter assays, catalytic mutant analysis Cell Death and Differentiation Medium 31358914
2020 JMJD6 negatively regulates antiviral innate immune signaling by recruiting the E3 ubiquitin ligase RNF5 to promote K48-linked ubiquitination and degradation of activated IRF3, thereby reducing type-I interferon production in response to cytosolic RNA and RNA viruses. Co-IP/proteomic screen, ubiquitination assay, JMJD6 KO (piggyBac), IFN-I production assay, viral replication assay PLoS Pathogens High 33684176
2021 JMJD6 is essential for hematopoietic stem cell (HSC) self-renewal and multilineage reconstitution; loss of Jmjd6 elevates mitochondrial oxidative phosphorylation (OXPHOS) and ROS, and antioxidant (N-acetyl-l-cysteine) rescues HSC depletion, establishing OXPHOS-mediated ROS as causal in the HSC failure. Hematopoietic-specific conditional KO, serial transplantation, mitochondrial respiration assays, ROS measurement, antioxidant rescue Blood Advances High 33560400
2021 JMJD6 knockdown reduces recruitment of U2AF65 to AR pre-mRNA and decreases AR-V7 splice variant levels in prostate cancer; mutagenesis of the JMJD6 catalytic machinery abrogates AR-V7 generation. siRNA screen, JMJD6 KD, RNA immunoprecipitation (U2AF65-AR pre-mRNA), catalytic mutagenesis Cancer Research Medium 33822745
2022 Mass spectrometry proteomics identifies 150 sites of JMJD6-catalyzed lysine hydroxylation on 48 protein substrates including 19 sites on BRD4; hydroxylations occur predominantly within unstructured lysine-rich regions; nearly all substrates are associated with membraneless organelle formation, suggesting a role for JMJD6 in regulating liquid-liquid phase separation. MS with lysine derivatization (propionic anhydride) and nontryptic proteolysis; JMJD6 KO comparison Proceedings of the National Academy of Sciences High 35930668
2022 JMJD6 interacts with RBM39 and co-occupies the DGAT1 gene promoter together with H3K4me3 to induce DGAT1 expression, driving lipid droplet formation and ccRCC tumorigenesis; JMJD6 silencing reduces DGAT1 and lipid droplet formation. Co-IP, ChIP-seq, RNA-seq, siRNA screen, in vitro and in vivo tumor models Molecular Cell Medium 35764091
2022 JMJD6 regulates splicing of its own pre-mRNA producing two isoforms (JMJD6-2 and JMJD6-Ex5) with distinct interactomes; JMJD6-2 interacts with SR/RS-domain splicing factors and inhibits exon inclusion in a splicing reporter, whereas JMJD6-Ex5 interacts with SMN complex, hnRNPs, UBF, and FCP1 without splicing inhibitory effect. LC-MS/MS immunoprecipitation, HIV-based splicing reporter, siRNA knockdown of jmjd6 affecting isoform ratios International Journal of Molecular Sciences Medium 32927736
2024 JMJD6 acts as a hub connecting pre-mRNA splicing and glutamine metabolism in MYC-driven neuroblastoma; JMJD6 physically interacts with RNA-binding proteins involved in splicing and controls alternative splicing of glutaminase isoforms (KGA vs GAC); JMJD6 also complexes with splicing factor RBM39, linking its function to indisulam (RBM39 degrader) sensitivity. Co-IP (JMJD6-RNA binding protein complex), RNA-seq splicing analysis, metabolic assays, cellular transformation assay eLife Medium 38488852
2024 JMJD6 is a transcriptional target of HSF1 and reduces HSP70 R469 monomethylation to disrupt HSP70-HSF1 repressive complexes, resulting in enhanced HSF1 activation; JMJD6 and HSF1 form a positive feedback circuit promoting cellular adaptation to proteotoxic stress. Genome-wide RNAi screen with HSR reporter, Co-IP (HSP70-HSF1), methylation assay, JMJD6 KD/OE, ChIP Proceedings of the National Academy of Sciences Medium 38985769
2020 JMJD6 participates in rDNA damage response: it is rapidly recruited to nucleolar DNA damage, is crucial for relocalisation of rDNA into nucleolar caps, interacts with nucleolar protein Treacle (by MS), and modulates Treacle-NBS1 interaction; JMJD6-deficient cells show increased sensitivity to nucleolar DNA damage and loss/rearrangements of rDNA repeats. Live imaging (microirradiation), mass spectrometry interactome, KD with rDNA stability and sensitivity readouts PLoS Genetics Medium 32598339
2025 JMJD6 recruits mediator subunits Med1/14 to assemble de novo enhancers at glutathione biosynthesis genes (SLC7A11, GCLM, ME1) together with ATF4, independent of androgen receptor; SPOP-mutant prostate cancer accumulates JMJD6 via impaired proteasomal degradation, conferring ferroptosis resistance through enhanced glutathione metabolism. Co-IP (JMJD6-Med1/14-ATF4), ChIP-seq (enhancer-promoter loops), proteasome inhibition assays, ferroptosis induction assays, in vivo preclinical models Cancer Research Medium 39903850
2017 JMJD6 was found secreted as a soluble protein in the extracellular matrix; recombinant JMJD6 binds collagen type I (Coll-I) and distinct JMJD6 peptides interfere with collagen fibrillogenesis, collagen-fibronectin interaction, and tumor cell adhesion to collagen substrate; antibody blockade of JMJD6-Coll-I interaction reduces fibrosis and prevents lung metastases in mice. Recombinant protein binding assay, collagen fibrillogenesis assay, Co-IP, in vivo tumor models FASEB Journal Medium 28790175
2021 MALDI-TOF identified fibronectin as a novel substrate of JMJD6-mediated lysyl hydroxylation; this hydroxylation precedes fibronectin glycosylation, deposition, and degradation; JMJD6 knockdown in placental mesenchymal cells impairs fibronectin fibril formation and lysosomal degradation, and Fe2+ supplementation rescues JMJD6 activity and fibronectin homeostasis. MALDI-TOF, JMJD6 KD, Fe2+ rescue, fibronectin assembly and lysosomal degradation assays, time-lapse migration imaging Frontiers in Cell and Developmental Biology Medium 34055782
2015 Jmjd6 in Xenopus embryos interacts with Tcf7l1 (Tcf3) transcriptional repressor and derepresses it by displacing the Groucho corepressor; Jmjd6 antagonizes Tcf7l1-mediated repression, enhances β-catenin-induced gene activation, and is required for anteroposterior axis patterning in Xenopus embryogenesis. Co-IP, transcriptional reporter assay, morpholino loss-of-function, Xenopus embryo axis defect analysis Journal of Biological Chemistry Medium 26157142
2013 Iron availability modulates Jmjd6-dependent U2AF65 lysyl hydroxylation, which in turn influences the ratio of correct to aberrant FECH mRNA splice products; siRNA knockdown of Jmjd6 phenocopies iron deficiency in shifting FECH splicing toward aberrant products. siRNA KD, splicing quantification, iron chelation experiments Blood Cells, Molecules and Diseases Medium 23787363
2018 JMJD6 demethylates H4R3me2a at the PDEC1 (PDE1C) promoter in adipose-derived mesenchymal stem cells, suppressing PDE1C expression and thereby reducing intracellular cAMP and cGMP levels; JMJD6 knockdown increases PDE1C and enhances cell proliferation and migration, effects reversed by PDE1C inhibition. ChIP-qPCR, siRNA knockdown, PDE1C inhibitor rescue, cAMP/cGMP measurement Stem Cell Research and Therapy Medium 30092848

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 JMJD6 is a histone arginine demethylase. Science (New York, N.Y.) 516 17947579
2013 Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 326 24360279
2009 Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science (New York, N.Y.) 325 19574390
2011 Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proceedings of the National Academy of Sciences of the United States of America 121 21300889
2014 JMJD6 promotes colon carcinogenesis through negative regulation of p53 by hydroxylation. PLoS biology 116 24667498
2004 Identification of cardiac malformations in mice lacking Ptdsr using a novel high-throughput magnetic resonance imaging technique. BMC developmental biology 116 15615595
2013 Lysyl 5-hydroxylation, a novel histone modification, by Jumonji domain containing 6 (JMJD6). The Journal of biological chemistry 111 23303181
2010 Interaction of JMJD6 with single-stranded RNA. Proceedings of the National Academy of Sciences of the United States of America 90 20679243
2015 The oxygenase Jmjd6--a case study in conflicting assignments. The Biochemical journal 75 25997831
2019 JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma. Nature communications 73 31346162
2018 JMJD6 Licenses ERα-Dependent Enhancer and Coding Gene Activation by Modulating the Recruitment of the CARM1/MED12 Co-activator Complex. Molecular cell 73 29628309
2010 Crystal structure of the 2-oxoglutarate- and Fe(II)-dependent lysyl hydroxylase JMJD6. Journal of molecular biology 70 20684070
2014 JMJD6 regulates ERα methylation on arginine. PloS one 69 24498420
2016 PCAF-mediated acetylation of transcriptional factor HOXB9 suppresses lung adenocarcinoma progression by targeting oncogenic protein JMJD6. Nucleic acids research 66 27613418
2017 Histone arginine demethylase JMJD6 is linked to stress granule assembly through demethylation of the stress granule-nucleating protein G3BP1. The Journal of biological chemistry 63 28972166
2010 Analysis of Jmjd6 cellular localization and testing for its involvement in histone demethylation. PloS one 61 21060799
2018 JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4. International journal of cancer 59 30125344
2013 High expression of JMJD6 predicts unfavorable survival in lung adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 57 23595221
2017 JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Molecular cancer 56 29187213
2016 The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis. Clinical epigenetics 56 27081402
2014 Jumonji domain containing protein 6 (Jmjd6) modulates splicing and specifically interacts with arginine-serine-rich (RS) domains of SR- and SR-like proteins. Nucleic acids research 56 24914048
2010 Crystal Structure of the 2-Oxoglutarate- and Fe(II)-Dependent Lysyl Hydroxylase JMJD6. Journal of molecular biology 55 20685276
2018 JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity. Oncogene 49 30185813
2011 The 2-oxoglutarate-dependent oxygenase JMJD6 catalyses oxidation of lysine residues to give 5S-hydroxylysine residues. Chembiochem : a European journal of chemical biology 49 22238144
2015 Role of JMJD6 in Breast Tumourigenesis. PloS one 48 25951181
2015 Elevated expression of JMJD6 is associated with oral carcinogenesis and maintains cancer stemness properties. Carcinogenesis 48 26645717
2022 An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Molecular cell 46 35764091
2017 Jmjd6, a JmjC Dioxygenase with Many Interaction Partners and Pleiotropic Functions. Frontiers in genetics 45 28360925
2017 MiR-770 inhibits tumorigenesis and EMT by targeting JMJD6 and regulating WNT/β-catenin pathway in non-small cell lung cancer. Life sciences 45 28882645
2012 The hydroxylation activity of Jmjd6 is required for its homo-oligomerization. Journal of cellular biochemistry 43 22189873
2019 Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal transduction and targeted therapy 41 31637004
2017 JMJD6 and U2AF65 co-regulate alternative splicing in both JMJD6 enzymatic activity dependent and independent manner. Nucleic acids research 41 27899633
2020 Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood 40 32068780
2021 JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer research 38 33822745
2017 Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal (ET) Domain of BRD4. Scientific reports 38 29176719
2008 Genomic structure and expression of Jmjd6 and evolutionary analysis in the context of related JmjC domain containing proteins. BMC genomics 38 18564434
2013 The polyserine domain of the lysyl-5 hydroxylase Jmjd6 mediates subnuclear localization. The Biochemical journal 36 23688307
2014 Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Scientific reports 33 25219359
2013 Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF(65.). Blood cells, molecules & diseases 31 23787363
2015 Intronic regulation of Aire expression by Jmjd6 for self-tolerance induction in the thymus. Nature communications 30 26531897
2019 Biochemical and structural investigations clarify the substrate selectivity of the 2-oxoglutarate oxygenase JMJD6. The Journal of biological chemistry 29 31147442
2022 Widespread hydroxylation of unstructured lysine-rich protein domains by JMJD6. Proceedings of the National Academy of Sciences of the United States of America 28 35930668
2020 JMJD6 cleaves MePCE to release positive transcription elongation factor b (P-TEFb) in higher eukaryotes. eLife 28 32048991
2020 Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer. BMC cancer 26 33246425
2017 Bifunctional Enzyme JMJD6 Contributes to Multiple Disease Pathogenesis: New Twist on the Old Story. Biomolecules 26 28587176
2016 Role of Jumonji C-domain containing protein 6 (JMJD6) in infectivity of foot-and-mouth disease virus. Virology 26 26896934
2022 A specific JMJD6 inhibitor potently suppresses multiple types of cancers both in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 25 35969736
2018 LncRNA-MALAT1 promotes CPC proliferation and migration in hypoxia by up-regulation of JMJD6 via sponging miR-125. Biochemical and biophysical research communications 25 29605300
2022 Role of the Epigenetic Modifier JMJD6 in Tumor Development and Regulation of Immune Response. Frontiers in immunology 24 35359945
2021 Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. Clinical and translational medicine 24 33634984
2017 Demethylase JMJD6 as a New Regulator of Interferon Signaling: Effects of HCV and Ethanol Metabolism. Cellular and molecular gastroenterology and hepatology 23 29693039
2018 Compromised JMJD6 Histone Demethylase Activity Affects VHL Gene Repression in Preeclampsia. The Journal of clinical endocrinology and metabolism 22 29373688
2017 Inhibition of JMJD6 expression reduces the proliferation, migration and invasion of neuroglioma stem cells. Neoplasma 22 28592121
2021 JMJD6 negatively regulates cytosolic RNA induced antiviral signaling by recruiting RNF5 to promote activated IRF3 K48 ubiquitination. PLoS pathogens 20 33684176
2020 JMJD6 participates in the maintenance of ribosomal DNA integrity in response to DNA damage. PLoS genetics 20 32598339
2019 JMJD6 modulates DNA damage response through downregulating H4K16ac independently of its enzymatic activity. Cell death and differentiation 19 31358914
2018 JMJD6 exerts function in neuropathic pain by regulating NF‑κB following peripheral nerve injury in rats. International journal of molecular medicine 19 29620141
2023 JMJD6-BRD4 complex stimulates lncRNA HOTAIR transcription by binding to the promoter region of HOTAIR and induces radioresistance in liver cancer stem cells. Journal of translational medicine 18 37880710
2018 Ras-Induced miR-146a and 193a Target Jmjd6 to Regulate Melanoma Progression. Frontiers in genetics 18 30619488
2009 Endogenous Jmjd6 gene product is expressed at the cell surface and regulates phagocytosis in immature monocyte-like activated THP-1 cells. Journal of cellular physiology 17 19492415
2018 JMJD6 induces HOTAIR, an oncogenic lincRNA, by physically interacting with its proximal promoter. The Biochemical journal 16 29229759
2025 JMJD6 K375 acetylation restrains lung cancer progression by enhancing METTL14/m6A/SLC3A2 axis mediated cell ferroptosis. Journal of translational medicine 15 40011892
2019 In Silico Discovery of JMJD6 Inhibitors for Cancer Treatment. ACS medicinal chemistry letters 15 31857835
2021 LINC00839/miR-519d-3p/JMJD6 axis modulated cell viability, apoptosis, migration and invasiveness of lung cancer cells. Folia histochemica et cytobiologica 14 34734406
2015 JmjC Domain-containing Protein 6 (Jmjd6) Derepresses the Transcriptional Repressor Transcription Factor 7-like 1 (Tcf7l1) and Is Required for Body Axis Patterning during Xenopus Embryogenesis. The Journal of biological chemistry 14 26157142
2021 JMJD6 promotes self-renewal and regenerative capacity of hematopoietic stem cells. Blood advances 13 33560400
2024 Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor. eLife 12 38488852
2023 JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit. Acta pharmacologica Sinica 12 37186122
2021 Discovery of a new class of JMJD6 inhibitors and structure-activity relationship study. Bioorganic & medicinal chemistry letters 12 33991627
2022 Oxygen-dependent regulation of E3(SCF)ubiquitin ligases and a Skp1-associated JmjD6 homolog in development of the social amoeba Dictyostelium. The Journal of biological chemistry 11 35933019
2021 The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression. Cancer cell international 11 33430885
2020 LncRNA ZFPM2-AS1 aggravates the malignant development of breast cancer via upregulating JMJD6. European review for medical and pharmacological sciences 11 33215431
2019 Livin promotes colon cancer progression by regulation of H2A.XY39ph via JMJD6. Life sciences 11 31445935
2017 Antibody-mediated blockade of JMJD6 interaction with collagen I exerts antifibrotic and antimetastatic activities. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 11 28790175
2020 Differential regulation of sFlt-1 splicing by U2AF65 and JMJD6 in placental-derived and endothelial cells. Bioscience reports 10 32039444
2025 JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer. Cancer research 9 39903850
2023 JMJD6 Shapes a Pro-tumor Microenvironment via ANXA1-Dependent Macrophage Polarization in Breast Cancer. Molecular cancer research : MCR 9 36867680
2018 Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells. Stem cell research & therapy 9 30092848
2016 Pathogenesis and micro-anatomic characterization of a cell-adapted mutant foot-and-mouth disease virus in cattle: Impact of the Jumonji C-domain containing protein 6 (JMJD6) and route of inoculation. Virology 9 26914509
2021 JMJD6 Dysfunction Due to Iron Deficiency in Preeclampsia Disrupts Fibronectin Homeostasis Resulting in Diminished Trophoblast Migration. Frontiers in cell and developmental biology 8 34055782
2017 Insights into Jumonji C-domain containing protein 6 (JMJD6): a multifactorial role in foot-and-mouth disease virus replication in cells. Virus genes 8 28364140
2024 An HSF1-JMJD6-HSP feedback circuit promotes cell adaptation to proteotoxic stress. Proceedings of the National Academy of Sciences of the United States of America 7 38985769
2022 The Novel Protease Activities of JMJD5-JMJD6-JMJD7 and Arginine Methylation Activities of Arginine Methyltransferases Are Likely Coupled. Biomolecules 7 35327545
2022 Loss of function of an Arabidopsis homologue of JMJD6 suppresses the dwarf phenotype of acl5, a mutant defective in thermospermine biosynthesis. FEBS letters 7 35962471
2022 JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells. Frontiers in endocrinology 7 36419768
2019 Promotion of adipogenesis by JMJD6 requires the AT hook-like domain and is independent of its catalytic function. PloS one 7 31430278
2019 KRas-ERK signalling promotes the onset and maintenance of uveal melanoma through regulating JMJD6-mediated H2A.X phosphorylation at tyrosine 39. Artificial cells, nanomedicine, and biotechnology 7 31736361
2023 c-Jun-mediated JMJD6 restoration enhances resistance of liver cancer to radiotherapy through the IL-4-activated ERK pathway. Cell biology international 6 37070787
2020 Analysis of Amino Acid Mutations of the Foot-and-Mouth Disease Virus Serotype O Using both Heparan Sulfate and JMJD6 Receptors. Viruses 6 32927791
2025 Targeting JMJD6/PPARγ/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma. Oncogene 5 41028904
2020 JMJD6 Regulates Splicing of Its Own Gene Resulting in Alternatively Spliced Isoforms with Different Nuclear Targets. International journal of molecular sciences 5 32927736
2018 Normalizing JMJD6 Expression in Rat Spinal Dorsal Horn Alleviates Hyperalgesia Following Chronic Constriction Injury. Frontiers in neuroscience 5 30131674
2022 MiR-298 suppresses the malignant progression of osteosarcoma by targeting JMJD6. European review for medical and pharmacological sciences 4 35442509
2022 Design and synthesis of N-(1-(6-(substituted phenyl)-pyridazin-3-yl)-piperidine-3-yl)-amine derivatives as JMJD6 inhibitors. Bioorganic chemistry 4 36116323
2022 The JMJD6/HURP axis promotes cell migration via NF-κB-dependent centrosome repositioning and Cdc42-mediated Golgi repositioning. Journal of cellular physiology 4 36250981
2021 Computational and Mass Spectrometry-Based Approach Identify Deleterious Non-Synonymous Single Nucleotide Polymorphisms (nsSNPs) in JMJD6. Molecules (Basel, Switzerland) 4 34361805
2022 Impact of JMJD6 on intrahepatic cholangiocarcinoma. Molecular and clinical oncology 3 35911665
2025 JMJD6-driven epigenetic activation of COL4A2 reprograms glioblastoma vascularization via integrin α1β1-dependent PI3K/MAPK signaling. Acta neuropathologica communications 2 40993804
2024 Oncogenic DDX46 promotes pancreatic cancer development and gemcitabine resistance by facilitating the JMJD6/CDK4 signaling pathway. Neoplasma 2 38764294
2022 Jmjd6 regulates ES cell homeostasis and enhances reprogramming efficiency. Heliyon 2 35846449